Evidence map›Paper›PMID 39980283›Full record

ReviewInfectious disorders drug targets2025

Clinical and

Naina Mohamed Pakkir Maideen, Rajkapoor Balasubramanian, Kumar Balasubramanian, Mohamed Harsath Jahir Hussain, Mohamed Fahath Shahul Hameed, Rethesh Senthil

Abstract readReview
PubMed Publisher
In one paragraph

Review in Infectious disorders drug targets, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Naina Mohamed Pakkir MaideenDepartment of Pharmacology, Pharmacologist, Dubai Health Authority, Dubai, UAE.
Rajkapoor BalasubramanianDepartment of Pharmacology, J.K.K. Nattraja College of Pharmacy, Komarapalayam, Tamil Nadu, India.
Kumar BalasubramanianDepartment of Pharmacy Practice, Swathi College of Pharmacy, Nellore, AP, India.
Mohamed Harsath Jahir HussainRatnam Institute of Pharmacy, Nellore, Andhra Pradesh, India.
Mohamed Fahath Shahul HameedVenkateshwara Institute of Medical Sciences, Gajraula, Uttar Pradesh, India.
Rethesh SenthilMahathma Gandhi Medical College and Research Institute, Pondicherry, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHepatitis C Virus (HCV) and Hepatitis B Virus (HBV) can cause acute and chronic viral infections. Due to their higher costs, potential side effects and drug interactions, and associated risks, some patients with HCV and HBV infections may not be able to afford conventional antiviral medications.

objectiveThe goal of this review paper is to highlight the advantages of Nigella sativa, or black seeds, in the treatment of patients with HCV and HBV infections.

methodsMedline/Pubmed/PMC, Scopus, Web of Science, Google Scholar, Science Direct, Ebsco, Embase, and reference lists were searched to locate the research studies that assessed the effects of different black seed (N. sativa) preparations on the telltale signs and symptoms of HCV and HBV infections.

resultsNumerous preclinical and clinical investigations have suggested that black seeds (N. sativa) may be effective against HCV and HBV infections. Furthermore, N. sativa, or black seeds, have demonstrated a range of pleiotropic effects, such as antiviral activity against multiple other viruses and anti-inflammatory, antioxidant, and immunomodulatory properties that can lessen the symptoms and indicators of HCV and HBV infections.

conclusionPatients with HCV and HBV infections may benefit from using black seeds (N. sativa) as an adjuvant therapy in addition to conventional therapy. Additional randomized controlled clinical trials would confirm the safety and effectiveness of Nigella sativa (black seeds) in treating HCV and HBV infections.

Indexed as

Antiviral AgentsHepatitis BHepatitis CNigella sativaPlant ExtractsSeedsAnimalsHepacivirusHepatitis B virusHumansPhytotherapyAntiviral AgentsPlant Extractsblack seedsHepatitis B virushepatitis C viruskalonjiNigella sativathymoquinone.

Identifiers

PMID39980283

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.